CHUGAI PHARMA, Jan-Mar (1Q) Net Income Increases by 19%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Apr 24, 2026 5:00 pm JST Earnings

4519 CHUGAI PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

CHUGAI PHARMACEUTICAL CO., LTD. <4519> [TSE Prime] announced its financial results (based on IFRS) after the market closed on April 24th (17:00). The consolidated net income for the first quarter of the fiscal year ending December 2026 (January to March) increased 18.7% from the same period last year, reaching 115 billion yen.

In the most recent three-month period, from January to March (1Q), the operating profit margin rose from 47.4% in the same period last year to 49.3%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Mar, 2024	236,949	99,874	99,889	74,401	45.2	38.6	Apr 24, 2024	IFRS
Jan - Mar, 2025	288,459	136,651	135,829	97,234	59.1	50.0	Apr 24, 2025	IFRS
Jan - Mar, 2026	321,747	158,765	160,197	115,418	70.1	ー	Apr 24, 2026	IFRS
YoY	+11.5%	+16.2%	+17.9%	+18.7%	+18.7%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2025	578,463	273,342	271,830	194,389	118.1	125	Jul 24, 2025	IFRS
Jan - Jun, 2026 Guidance	ー	ー	ー	ー	－	66	Jan 29, 2026	IFRS
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2024	1,170,611	542,002	543,034	387,317	235.4	98	Jan 30, 2025	IFRS
Dec, 2025	1,257,941	598,833	597,807	434,012	263.7	272	Jan 29, 2026	IFRS
Dec, 2026 Guidance	1,345,000	ー	ー	ー	－	132	Jan 29, 2026	IFRS
YoY	+6.9%	－	－	－	－

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2025	288,459	136,651	135,829	97,234	59.1	47.4	Apr 24, 2025	IFRS
Apr - Jun, 2025	290,004	136,691	136,001	97,155	59.0	47.1	Jul 24, 2025	IFRS
Jul - Sep, 2025	333,177	156,485	156,072	111,213	67.6	47.0	Oct 24, 2025	IFRS
Oct - Dec, 2025	346,301	169,006	169,905	128,410	78.0	48.8	Jan 29, 2026	IFRS
Jan - Mar, 2026	321,747	158,765	160,197	115,418	70.1	49.3	Apr 24, 2026	IFRS
YoY	+11.5%	+16.2%	+17.9%	+18.7%	+18.7%